Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Avalyn Pharma Inc.AVLN · Entity 4662 | 10% owner · See Remark 1 | May 01, 2026 | May 05, 2026 |
| Beam Therapeutics Inc.BEAM · Entity 4227 | 10% owner · See Remark 1 | June 25, 2026 | June 29, 2026 |
| Fidelity Multi-Strategy Credit FundNONE · Entity 74426 | 10% owner · See Remark 1 | May 19, 2023 | May 26, 2023 |
| Rallybio CorpRLYB · Entity 6838 | 10% owner · See Remark 1 | March 04, 2026 | March 10, 2026 |
| Sana Biotechnology, Inc.SANA · Entity 4870 | 10% owner · See Remark 1 | January 08, 2025 | January 10, 2025 |
| Structure Therapeutics Inc.GPCR · Entity 1222 | 10% owner · See Remark 1 | July 22, 2026 | July 24, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Avalyn Pharma Inc.
Report date May 01, 2026 · Filed May 05, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | IndirectF-Prime Capital Partners Healthcare Fund V LP | 727,585 |
Reported balance
After 2026-05-01 transaction · row 1
Account identity is unresolved; indirect or unspecified ownership is not merged.
1 source rowRow 1 · 2026-05-01 · Conversion · Acquired 727,585 · Balance 727,585 F1: On May 1, 2026, in connection with the completion of the issuer's initial public offering, each share of Series A Preferred Stock, Series B Preferred Stock, Series C-1 Preferred Stock, Series C-2 Preferred Stock, and Series D Preferred Stock converted on a 1-for-1 basis into shares of Common Stock. |
| Common StockSEC Table I · non-derivative | IndirectF-Prime Capital Partners Healthcare Fund V LP | 807,876 |
Reported balance
After 2026-05-01 transaction · row 2
Account identity is unresolved; indirect or unspecified ownership is not merged.
1 source rowRow 2 · 2026-05-01 · Conversion · Acquired 80,291 · Balance 807,876 F1: On May 1, 2026, in connection with the completion of the issuer's initial public offering, each share of Series A Preferred Stock, Series B Preferred Stock, Series C-1 Preferred Stock, Series C-2 Preferred Stock, and Series D Preferred Stock converted on a 1-for-1 basis into shares of Common Stock. |
| Common StockSEC Table I · non-derivative | IndirectF-Prime Capital Partners Healthcare Fund V LP | 1,680,744 |
Reported balance
After 2026-05-01 transaction · row 3
Account identity is unresolved; indirect or unspecified ownership is not merged.
1 source rowRow 3 · 2026-05-01 · Conversion · Acquired 872,868 · Balance 1,680,744 F1: On May 1, 2026, in connection with the completion of the issuer's initial public offering, each share of Series A Preferred Stock, Series B Preferred Stock, Series C-1 Preferred Stock, Series C-2 Preferred Stock, and Series D Preferred Stock converted on a 1-for-1 basis into shares of Common Stock. |
| Common StockSEC Table I · non-derivative | IndirectF-Prime Capital Partners Healthcare Fund V LP | 1,906,587 |
Reported balance
After 2026-05-01 transaction · row 4
Account identity is unresolved; indirect or unspecified ownership is not merged.
1 source rowRow 4 · 2026-05-01 · Conversion · Acquired 225,843 · Balance 1,906,587 F1: On May 1, 2026, in connection with the completion of the issuer's initial public offering, each share of Series A Preferred Stock, Series B Preferred Stock, Series C-1 Preferred Stock, Series C-2 Preferred Stock, and Series D Preferred Stock converted on a 1-for-1 basis into shares of Common Stock. |
| Common StockSEC Table I · non-derivative | IndirectF-Prime Capital Partners Healthcare Fund V LP | 2,284,535 |
Reported balance
After 2026-05-01 transaction · row 5
Account identity is unresolved; indirect or unspecified ownership is not merged.
1 source rowRow 5 · 2026-05-01 · Conversion · Acquired 377,948 · Balance 2,284,535 F1: On May 1, 2026, in connection with the completion of the issuer's initial public offering, each share of Series A Preferred Stock, Series B Preferred Stock, Series C-1 Preferred Stock, Series C-2 Preferred Stock, and Series D Preferred Stock converted on a 1-for-1 basis into shares of Common Stock. |
| Series A Preferred StockSEC Table II · derivative / convertible security | IndirectF-Prime Capital Partners Healthcare Fund V LP | 0 |
Reported balance
After 2026-05-01 transaction · row 6
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 6 · 2026-05-01 · Conversion · Disposed 727,585 · Balance 0 F1: On May 1, 2026, in connection with the completion of the issuer's initial public offering, each share of Series A Preferred Stock, Series B Preferred Stock, Series C-1 Preferred Stock, Series C-2 Preferred Stock, and Series D Preferred Stock converted on a 1-for-1 basis into shares of Common Stock. |
| Series B Preferred StockSEC Table II · derivative / convertible security | IndirectF-Prime Capital Partners Healthcare Fund V LP | 0 |
Reported balance
After 2026-05-01 transaction · row 7
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 7 · 2026-05-01 · Conversion · Disposed 80,291 · Balance 0 F1: On May 1, 2026, in connection with the completion of the issuer's initial public offering, each share of Series A Preferred Stock, Series B Preferred Stock, Series C-1 Preferred Stock, Series C-2 Preferred Stock, and Series D Preferred Stock converted on a 1-for-1 basis into shares of Common Stock. |
| Series C-1 Preferred StockSEC Table II · derivative / convertible security | IndirectF-Prime Capital Partners Healthcare Fund V LP | 0 |
Reported balance
After 2026-05-01 transaction · row 8
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 8 · 2026-05-01 · Conversion · Disposed 872,868 · Balance 0 F1: On May 1, 2026, in connection with the completion of the issuer's initial public offering, each share of Series A Preferred Stock, Series B Preferred Stock, Series C-1 Preferred Stock, Series C-2 Preferred Stock, and Series D Preferred Stock converted on a 1-for-1 basis into shares of Common Stock. |
| Series C-2 Preferred StockSEC Table II · derivative / convertible security | IndirectF-Prime Capital Partners Healthcare Fund V LP | 0 |
Reported balance
After 2026-05-01 transaction · row 9
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 9 · 2026-05-01 · Conversion · Disposed 225,843 · Balance 0 F1: On May 1, 2026, in connection with the completion of the issuer's initial public offering, each share of Series A Preferred Stock, Series B Preferred Stock, Series C-1 Preferred Stock, Series C-2 Preferred Stock, and Series D Preferred Stock converted on a 1-for-1 basis into shares of Common Stock. |
| Series D Preferred StockSEC Table II · derivative / convertible security | IndirectF-Prime Capital Partners Healthcare Fund V LP | 0 |
Reported balance
After 2026-05-01 transaction · row 10
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 10 · 2026-05-01 · Conversion · Disposed 377,948 · Balance 0 F1: On May 1, 2026, in connection with the completion of the issuer's initial public offering, each share of Series A Preferred Stock, Series B Preferred Stock, Series C-1 Preferred Stock, Series C-2 Preferred Stock, and Series D Preferred Stock converted on a 1-for-1 basis into shares of Common Stock. |
Filing footnotes · ownership attribution and instrument terms
F1: On May 1, 2026, in connection with the completion of the issuer's initial public offering, each share of Series A Preferred Stock, Series B Preferred Stock, Series C-1 Preferred Stock, Series C-2 Preferred Stock, and Series D Preferred Stock converted on a 1-for-1 basis into shares of Common Stock.
Beam Therapeutics Inc.
Report date June 25, 2026 · Filed June 29, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | IndirectF-Prime Capital Partners Healthcare Fund V LP | 1,106,071 |
Reported balance
After 2026-06-25 transaction · row 1
Account identity is unresolved; indirect or unspecified ownership is not merged.
1 source rowRow 1 · 2026-06-25 · Sale · Disposed 33,372 · Balance 1,106,071 F1: The price reported for this transaction is the weighted average price of multiple trades at prices ranging from $35.00 to $35.39. FMR LLC hereby undertakes to provide upon request by the Commission staff, the issuer, or a security holder of the issuer full information. |
| Common StockSEC Table I · non-derivative | IndirectF-Prime Capital Partners Healthcare Fund V LP | 854,583 |
Reported balance
After 2026-06-26 transaction · row 2
Account identity is unresolved; indirect or unspecified ownership is not merged.
1 source rowRow 2 · 2026-06-26 · Sale · Disposed 251,488 · Balance 854,583 F2: The price reported for this transaction is the weighted average price of multiple trades at prices ranging from $35.00 to $35.88. FMR LLC hereby undertakes to provide upon request by the Commission staff, the issuer, or a security holder of the issuer full information. |
| Common StockSEC Table I · non-derivative | IndirectFMR Capital, Inc. | 14 |
Reported balance
Holding disclosure · report date 2026-06-25 · row 3
Holding and transaction disclosures are not merged.
1 source rowRow 3 · Balance 14 |
| Common StockSEC Table I · non-derivative | IndirectShares held by persons and entities whose shares are subject to reporting by the undersigned. | 841,231 |
Reported balance
Holding disclosure · report date 2026-06-25 · row 4
Holding and transaction disclosures are not merged.
1 source rowRow 4 · Balance 841,231 |
Filing footnotes · ownership attribution and instrument terms
F1: The price reported for this transaction is the weighted average price of multiple trades at prices ranging from $35.00 to $35.39. FMR LLC hereby undertakes to provide upon request by the Commission staff, the issuer, or a security holder of the issuer full information.
F2: The price reported for this transaction is the weighted average price of multiple trades at prices ranging from $35.00 to $35.88. FMR LLC hereby undertakes to provide upon request by the Commission staff, the issuer, or a security holder of the issuer full information.
Fidelity Multi-Strategy Credit Fund
Report date May 19, 2023 · Filed May 26, 2023
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common Shares of Beneficial OwnershipSEC Table I · non-derivative | Direct | 2,500,000 |
Reported balance
Holding disclosure · report date 2023-05-19 · row 1
Holding and transaction disclosures are not merged.
1 source rowRow 1 · Balance 2,500,000 |
Rallybio Corp
Report date March 04, 2026 · Filed March 10, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | IndirectF-Prime Capital Partners Life Sciences Fund VI LP | 211,798 |
Reported balance
Holding disclosure · report date 2026-03-04 · row 1
Holding and transaction disclosures are not merged.
1 source rowRow 1 · Balance 211,798 |
Sana Biotechnology, Inc.
Report date January 08, 2025 · Filed January 10, 2025
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | IndirectF-Prime Capital Partners Life Sciences Fund VI LP | 4,732,423 |
Reported balance
After 2025-01-08 transaction · row 1
Account identity is unresolved; indirect or unspecified ownership is not merged.
1 source rowRow 1 · 2025-01-08 · Sale · Disposed 100,000 · Balance 4,732,423 F1: The price reported for this transaction is the weighted average price of multiple trades at prices ranging from $6.05 to $6.24. FMR LLC hereby undertakes to provide upon request by the Commission staff, the issuer, or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. |
| Common StockSEC Table I · non-derivative | IndirectF-Prime Capital Partners Life Sciences Fund VI LP | 4,707,423 |
Reported balance
After 2025-01-08 transaction · row 2
Account identity is unresolved; indirect or unspecified ownership is not merged.
1 source rowRow 2 · 2025-01-08 · Sale · Disposed 25,000 · Balance 4,707,423 F2: The price reported for this transaction is the weighted average price of multiple trades at prices ranging from $6.50 to $6.55. FMR LLC hereby undertakes to provide upon request by the Commission staff, the issuer, or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. |
| Common StockSEC Table I · non-derivative | IndirectF-Prime Capital Partners Life Sciences Fund VI LP | 4,542,511 |
Reported balance
After 2025-01-08 transaction · row 3
Account identity is unresolved; indirect or unspecified ownership is not merged.
1 source rowRow 3 · 2025-01-08 · Sale · Disposed 164,912 · Balance 4,542,511 F3: The price reported for this transaction is the weighted average price of multiple trades at prices ranging from $6.20 to $6.98. FMR LLC hereby undertakes to provide upon request by the Commission staff, the issuer, or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. |
| Common StockSEC Table I · non-derivative | IndirectF-Prime Capital Partners Life Sciences Fund VI LP | 4,541,511 |
Reported balance
After 2025-01-08 transaction · row 4
Account identity is unresolved; indirect or unspecified ownership is not merged.
1 source rowRow 4 · 2025-01-08 · Sale · Disposed 1,000 · Balance 4,541,511 |
| Common StockSEC Table I · non-derivative | IndirectFMR Capital, Inc. | 61 |
Reported balance
Holding disclosure · report date 2025-01-08 · row 5
Holding and transaction disclosures are not merged.
1 source rowRow 5 · Balance 61 |
Filing footnotes · ownership attribution and instrument terms
F1: The price reported for this transaction is the weighted average price of multiple trades at prices ranging from $6.05 to $6.24. FMR LLC hereby undertakes to provide upon request by the Commission staff, the issuer, or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
F2: The price reported for this transaction is the weighted average price of multiple trades at prices ranging from $6.50 to $6.55. FMR LLC hereby undertakes to provide upon request by the Commission staff, the issuer, or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
F3: The price reported for this transaction is the weighted average price of multiple trades at prices ranging from $6.20 to $6.98. FMR LLC hereby undertakes to provide upon request by the Commission staff, the issuer, or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
Structure Therapeutics Inc.
Report date July 22, 2026 · Filed July 24, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| American Depositary SharesSEC Table II · derivative / convertible security | IndirectF-Prime Capital Partners Life Sciences Advisors Fund VI LP | 1,369 |
Reported balance
After 2026-07-22 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2026-07-22 · Sale · Disposed 1,367 · Balance 1,369 F1: Reported securities are represented by American Depositary Shares, each of which represents three Ordinary Shares of the Issuer. F2: The price reported for this transaction is the weighted average price of multiple trades at prices ranging from $50.05 to $50.20. FMR LLC hereby undertakes to provide upon request by the Commission staff, the issuer, or a security holder of the issuer full information. |
| American Depositary SharesSEC Table II · derivative / convertible security | IndirectF-Prime Capital Partners Life Sciences Fund VI LP | 16,086 |
Reported balance
After 2026-07-22 transaction · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · 2026-07-22 · Sale · Disposed 16,085 · Balance 16,086 F1: Reported securities are represented by American Depositary Shares, each of which represents three Ordinary Shares of the Issuer. F2: The price reported for this transaction is the weighted average price of multiple trades at prices ranging from $50.05 to $50.20. FMR LLC hereby undertakes to provide upon request by the Commission staff, the issuer, or a security holder of the issuer full information. |
| Ordinary SharesSEC Table I · non-derivative | IndirectF-Prime Capital Partners Life Sciences Advisors Fund VI LP | 20,502 |
Reported balance
Holding disclosure · report date 2026-07-22 · row 1
Holding and transaction disclosures are not merged.
1 source rowRow 1 · Balance 20,502 |
| Ordinary SharesSEC Table I · non-derivative | IndirectF-Prime Capital Partners Life Sciences Fund VI LP | 241,275 |
Reported balance
Holding disclosure · report date 2026-07-22 · row 2
Holding and transaction disclosures are not merged.
1 source rowRow 2 · Balance 241,275 |
| American Depositary SharesSEC Table II · derivative / convertible security | IndirectShares held by persons and entities whose shares are subject to reporting by the undersigned | 1,515,558 |
Reported balance
Holding disclosure · report date 2026-07-22 · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · Balance 1,515,558 F1: Reported securities are represented by American Depositary Shares, each of which represents three Ordinary Shares of the Issuer. |
Filing footnotes · ownership attribution and instrument terms
F1: Reported securities are represented by American Depositary Shares, each of which represents three Ordinary Shares of the Issuer.
F2: The price reported for this transaction is the weighted average price of multiple trades at prices ranging from $50.05 to $50.20. FMR LLC hereby undertakes to provide upon request by the Commission staff, the issuer, or a security holder of the issuer full information.
Past disclosures · reporting ended (23)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
Aclaris Therapeutics, Inc.
Report date August 21, 2017 · Filed August 23, 2017
Section 16 reporting ended · disclosed 2017-08-23. Current position is not established by this disclosure.
No balance rows disclosed in this filing.
Bicara Therapeutics Inc.
Report date September 16, 2024 · Filed September 18, 2024
Section 16 reporting ended · disclosed 2024-09-18. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | IndirectF-Prime Capital Partners Life Sciences Fund VII LP | 10,818 |
Reported balance
After 2024-09-16 transaction · row 1
Account identity is unresolved; indirect or unspecified ownership is not merged.
1 source rowRow 1 · 2024-09-16 · Conversion · Acquired 10,818 · Balance 10,818 F1: On September 16, 2024, in connection with the completion of the issuer's initial public offering, each share of Series Seed, B, and C Preferred Shares converted on a 1-for-1 basis into shares of Common Stock. |
| Common StockSEC Table I · non-derivative | IndirectF-Prime Capital Partners Life Sciences Fund VII LP | 723,248 |
Reported balance
After 2024-09-16 transaction · row 2
Account identity is unresolved; indirect or unspecified ownership is not merged.
1 source rowRow 2 · 2024-09-16 · Conversion · Acquired 712,430 · Balance 723,248 F1: On September 16, 2024, in connection with the completion of the issuer's initial public offering, each share of Series Seed, B, and C Preferred Shares converted on a 1-for-1 basis into shares of Common Stock. |
| Common StockSEC Table I · non-derivative | IndirectF-Prime Capital Partners Life Sciences Fund VII LP | 1,115,333 |
Reported balance
After 2024-09-16 transaction · row 3
Account identity is unresolved; indirect or unspecified ownership is not merged.
1 source rowRow 3 · 2024-09-16 · Conversion · Acquired 392,085 · Balance 1,115,333 F1: On September 16, 2024, in connection with the completion of the issuer's initial public offering, each share of Series Seed, B, and C Preferred Shares converted on a 1-for-1 basis into shares of Common Stock. |
| Series Seed Preferred StockSEC Table II · derivative / convertible security | IndirectF-Prime Capital Partners Life Sciences Fund VII LP | 0 |
Reported balance
After 2024-09-16 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2024-09-16 · Conversion · Disposed 10,818 · Balance 0 F1: On September 16, 2024, in connection with the completion of the issuer's initial public offering, each share of Series Seed, B, and C Preferred Shares converted on a 1-for-1 basis into shares of Common Stock. |
| Series B Preferred StockSEC Table II · derivative / convertible security | IndirectF-Prime Capital Partners Life Sciences Fund VII LP | 0 |
Reported balance
After 2024-09-16 transaction · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · 2024-09-16 · Conversion · Disposed 712,430 · Balance 0 F1: On September 16, 2024, in connection with the completion of the issuer's initial public offering, each share of Series Seed, B, and C Preferred Shares converted on a 1-for-1 basis into shares of Common Stock. |
| Series C Preferred StockSEC Table II · derivative / convertible security | IndirectF-Prime Capital Partners Life Sciences Fund VII LP | 0 |
Reported balance
After 2024-09-16 transaction · row 6
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 6 · 2024-09-16 · Conversion · Disposed 392,085 · Balance 0 F1: On September 16, 2024, in connection with the completion of the issuer's initial public offering, each share of Series Seed, B, and C Preferred Shares converted on a 1-for-1 basis into shares of Common Stock. |
Filing footnotes · ownership attribution and instrument terms
F1: On September 16, 2024, in connection with the completion of the issuer's initial public offering, each share of Series Seed, B, and C Preferred Shares converted on a 1-for-1 basis into shares of Common Stock.
Caribou Biosciences, Inc.
Report date July 27, 2021 · Filed July 29, 2021
Section 16 reporting ended · disclosed 2021-07-29. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | IndirectF-Prime Capital Partners Healthcare Fund IV LP | 770,510 |
Reported balance
After 2021-07-27 transaction · row 1
Account identity is unresolved; indirect or unspecified ownership is not merged.
1 source rowRow 1 · 2021-07-27 · Conversion · Acquired 770,510 · Balance 770,510 F1: On July 27, 2021 , in connection with the completion of the issuer's initial public offering, each share of Series A-1 and Series B Preferred Stock converted into 1.818 share of Common Stock. |
| Common StockSEC Table I · non-derivative | IndirectF-Prime Capital Partners Healthcare Fund IV LP | 1,840,937 |
Reported balance
After 2021-07-27 transaction · row 2
Account identity is unresolved; indirect or unspecified ownership is not merged.
1 source rowRow 2 · 2021-07-27 · Conversion · Acquired 1,070,427 · Balance 1,840,937 F1: On July 27, 2021 , in connection with the completion of the issuer's initial public offering, each share of Series A-1 and Series B Preferred Stock converted into 1.818 share of Common Stock. |
| Common StockSEC Table I · non-derivative | IndirectF-Prime Capital Partners Healthcare Advisors Fund IV LP | 17,572 |
Reported balance
After 2021-07-27 transaction · row 3
Account identity is unresolved; indirect or unspecified ownership is not merged.
1 source rowRow 3 · 2021-07-27 · Conversion · Acquired 17,572 · Balance 17,572 F1: On July 27, 2021 , in connection with the completion of the issuer's initial public offering, each share of Series A-1 and Series B Preferred Stock converted into 1.818 share of Common Stock. |
| Common StockSEC Table I · non-derivative | IndirectImpresa Fund III Limited Partnership | 1,464,775 |
Reported balance
After 2021-07-27 transaction · row 4
Account identity is unresolved; indirect or unspecified ownership is not merged.
1 source rowRow 4 · 2021-07-27 · Conversion · Acquired 1,464,775 · Balance 1,464,775 F1: On July 27, 2021 , in connection with the completion of the issuer's initial public offering, each share of Series A-1 and Series B Preferred Stock converted into 1.818 share of Common Stock. |
| Series B Preferred StockSEC Table II · derivative / convertible security | IndirectF-Prime Capital Partners Healthcare Fund IV LP | 0 |
Reported balance
After 2021-07-27 transaction · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · 2021-07-27 · Conversion · Disposed 423,823 · Balance 0 F1: On July 27, 2021 , in connection with the completion of the issuer's initial public offering, each share of Series A-1 and Series B Preferred Stock converted into 1.818 share of Common Stock. |
| Series A-1 Preferred StockSEC Table II · derivative / convertible security | IndirectF-Prime Capital Partners Healthcare Fund IV LP | 0 |
Reported balance
After 2021-07-27 transaction · row 6
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 6 · 2021-07-27 · Conversion · Disposed 588,794 · Balance 0 F1: On July 27, 2021 , in connection with the completion of the issuer's initial public offering, each share of Series A-1 and Series B Preferred Stock converted into 1.818 share of Common Stock. |
| Series A-1 Preferred StockSEC Table II · derivative / convertible security | IndirectF-Prime Capital Partners Healthcare Advisors Fund IV LP | 0 |
Reported balance
After 2021-07-27 transaction · row 7
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 7 · 2021-07-27 · Conversion · Disposed 9,666 · Balance 0 F1: On July 27, 2021 , in connection with the completion of the issuer's initial public offering, each share of Series A-1 and Series B Preferred Stock converted into 1.818 share of Common Stock. |
| Series A-1 Preferred StockSEC Table II · derivative / convertible security | IndirectImpresa Fund III Limited Partnership | 0 |
Reported balance
After 2021-07-27 transaction · row 8
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 8 · 2021-07-27 · Conversion · Disposed 805,707 · Balance 0 F1: On July 27, 2021 , in connection with the completion of the issuer's initial public offering, each share of Series A-1 and Series B Preferred Stock converted into 1.818 share of Common Stock. |
Filing footnotes · ownership attribution and instrument terms
F1: On July 27, 2021 , in connection with the completion of the issuer's initial public offering, each share of Series A-1 and Series B Preferred Stock converted into 1.818 share of Common Stock.
Cogent Biosciences, Inc.
Report date April 03, 2018 · Filed April 05, 2018
Section 16 reporting ended · disclosed 2018-04-05. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | IndirectF-Prime Capital Partners Healthcare Fund IV LP | 349,462 |
Reported balance
After 2018-04-03 transaction · row 1
Account identity is unresolved; indirect or unspecified ownership is not merged.
1 source rowRow 1 · 2018-04-03 · Conversion · Acquired 349,462 · Balance 349,462 F1: On April 3, 2018, in connection with the completion of the issuer's initial public offering, each 1.5701314513884 shares of Series A and Series B Preferred Stock converted into 1 share of Common Stock. |
| Common StockSEC Table I · non-derivative | IndirectF-Prime Capital Partners Healthcare Fund IV LP | 358,063 |
Reported balance
After 2018-04-03 transaction · row 2
Account identity is unresolved; indirect or unspecified ownership is not merged.
1 source rowRow 2 · 2018-04-03 · Conversion · Acquired 8,601 · Balance 358,063 F1: On April 3, 2018, in connection with the completion of the issuer's initial public offering, each 1.5701314513884 shares of Series A and Series B Preferred Stock converted into 1 share of Common Stock. |
| Common StockSEC Table I · non-derivative | IndirectF-Prime Capital Partners Healthcare Fund IV LP | 452,115 |
Reported balance
After 2018-04-03 transaction · row 3
Account identity is unresolved; indirect or unspecified ownership is not merged.
1 source rowRow 3 · 2018-04-03 · Purchase · Acquired 94,052 · Balance 452,115 |
| Common StockSEC Table I · non-derivative | IndirectImpresa Fund III Limited Partnership | 1,890,701 |
Reported balance
After 2018-04-03 transaction · row 4
Account identity is unresolved; indirect or unspecified ownership is not merged.
1 source rowRow 4 · 2018-04-03 · Conversion · Acquired 1,890,701 · Balance 1,890,701 F1: On April 3, 2018, in connection with the completion of the issuer's initial public offering, each 1.5701314513884 shares of Series A and Series B Preferred Stock converted into 1 share of Common Stock. |
| Common StockSEC Table I · non-derivative | IndirectImpresa Fund III Limited Partnership | 1,937,235 |
Reported balance
After 2018-04-03 transaction · row 5
Account identity is unresolved; indirect or unspecified ownership is not merged.
1 source rowRow 5 · 2018-04-03 · Conversion · Acquired 46,534 · Balance 1,937,235 F1: On April 3, 2018, in connection with the completion of the issuer's initial public offering, each 1.5701314513884 shares of Series A and Series B Preferred Stock converted into 1 share of Common Stock. |
| Common StockSEC Table I · non-derivative | IndirectF-Prime Capital Partners Healthcare Advisors Fund IV LP | 22,682 |
Reported balance
After 2018-04-03 transaction · row 6
Account identity is unresolved; indirect or unspecified ownership is not merged.
1 source rowRow 6 · 2018-04-03 · Conversion · Acquired 22,682 · Balance 22,682 F1: On April 3, 2018, in connection with the completion of the issuer's initial public offering, each 1.5701314513884 shares of Series A and Series B Preferred Stock converted into 1 share of Common Stock. |
| Common StockSEC Table I · non-derivative | IndirectF-Prime Capital Partners Healthcare Advisors Fund IV LP | 23,240 |
Reported balance
After 2018-04-03 transaction · row 7
Account identity is unresolved; indirect or unspecified ownership is not merged.
1 source rowRow 7 · 2018-04-03 · Conversion · Acquired 558 · Balance 23,240 F1: On April 3, 2018, in connection with the completion of the issuer's initial public offering, each 1.5701314513884 shares of Series A and Series B Preferred Stock converted into 1 share of Common Stock. |
| Series A Preferred StockSEC Table II · derivative / convertible security | IndirectF-Prime Capital Partners Healthcare Fund IV LP | 0 |
Reported balance
After 2018-04-03 transaction · row 8
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 8 · 2018-04-03 · Conversion · Disposed 548,702 · Balance 0 F1: On April 3, 2018, in connection with the completion of the issuer's initial public offering, each 1.5701314513884 shares of Series A and Series B Preferred Stock converted into 1 share of Common Stock. |
| Series A Preferred StockSEC Table II · derivative / convertible security | IndirectImpresa Fund III Limited Partnership | 0 |
Reported balance
After 2018-04-03 transaction · row 9
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 9 · 2018-04-03 · Conversion · Disposed 2,968,650 · Balance 0 F1: On April 3, 2018, in connection with the completion of the issuer's initial public offering, each 1.5701314513884 shares of Series A and Series B Preferred Stock converted into 1 share of Common Stock. |
| Series A Preferred StockSEC Table II · derivative / convertible security | IndirectF-Prime Capital Partners Healthcare Advisors Fund IV LP | 0 |
Reported balance
After 2018-04-03 transaction · row 10
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 10 · 2018-04-03 · Conversion · Disposed 35,614 · Balance 0 F1: On April 3, 2018, in connection with the completion of the issuer's initial public offering, each 1.5701314513884 shares of Series A and Series B Preferred Stock converted into 1 share of Common Stock. |
| Series B Preferred StockSEC Table II · derivative / convertible security | IndirectF-Prime Capital Partners Healthcare Fund IV LP | 0 |
Reported balance
After 2018-04-03 transaction · row 11
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 11 · 2018-04-03 · Conversion · Disposed 13,505 · Balance 0 F1: On April 3, 2018, in connection with the completion of the issuer's initial public offering, each 1.5701314513884 shares of Series A and Series B Preferred Stock converted into 1 share of Common Stock. |
| Series B Preferred StockSEC Table II · derivative / convertible security | IndirectImpresa Fund III Limited Partnership | 0 |
Reported balance
After 2018-04-03 transaction · row 12
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 12 · 2018-04-03 · Conversion · Disposed 73,065 · Balance 0 F1: On April 3, 2018, in connection with the completion of the issuer's initial public offering, each 1.5701314513884 shares of Series A and Series B Preferred Stock converted into 1 share of Common Stock. |
| Series B Preferred StockSEC Table II · derivative / convertible security | IndirectF-Prime Capital Partners Healthcare Advisors Fund IV LP | 0 |
Reported balance
After 2018-04-03 transaction · row 13
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 13 · 2018-04-03 · Conversion · Disposed 877 · Balance 0 F1: On April 3, 2018, in connection with the completion of the issuer's initial public offering, each 1.5701314513884 shares of Series A and Series B Preferred Stock converted into 1 share of Common Stock. |
Filing footnotes · ownership attribution and instrument terms
F1: On April 3, 2018, in connection with the completion of the issuer's initial public offering, each 1.5701314513884 shares of Series A and Series B Preferred Stock converted into 1 share of Common Stock.
Denali Therapeutics Inc.
Report date April 09, 2018 · Filed April 11, 2018
Section 16 reporting ended · disclosed 2018-04-11. Current position is not established by this disclosure.
No balance rows disclosed in this filing.
Dimension Therapeutics, Inc.
Report date November 07, 2017 · Filed November 09, 2017
Section 16 reporting ended · disclosed 2017-11-09. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | IndirectImpresa Fund III Limited Partnership | 0 |
Reported balance
After 2017-11-07 transaction · row 1
Account identity is unresolved; indirect or unspecified ownership is not merged.
1 source rowRow 1 · 2017-11-07 · Other · Disposed 3,838,249 · Balance 0 |
| Common StockSEC Table I · non-derivative | IndirectF-Prime Capital Partners Healthcare Fund III LP | 0 |
Reported balance
After 2017-11-07 transaction · row 2
Account identity is unresolved; indirect or unspecified ownership is not merged.
1 source rowRow 2 · 2017-11-07 · Other · Disposed 1,050,016 · Balance 0 |
| Common StockSEC Table I · non-derivative | IndirectF-Prime Inc. | 0 |
Reported balance
After 2017-11-07 transaction · row 3
Account identity is unresolved; indirect or unspecified ownership is not merged.
1 source rowRow 3 · 2017-11-07 · Other · Disposed 5,057 · Balance 0 |
EXA CORP
Report date September 30, 2016 · Filed October 11, 2016
Section 16 reporting ended · disclosed 2016-10-11. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | IndirectBy Fidelity Ventures Limited | 0 |
Reported balance
After 2016-09-30 transaction · row 1
Account identity is unresolved; indirect or unspecified ownership is not merged.
1 source rowRow 1 · 2016-09-30 · Gift · Disposed 2,105,642 · Balance 0 |
Fidelity Private Credit Fund
Report date January 29, 2024 · Filed January 31, 2024
Section 16 reporting ended · disclosed 2024-01-31. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Class I Common Shares of Beneficial InterestSEC Table I · non-derivative | Direct | 1,280,001.754 |
Reported balance
Holding disclosure · report date 2024-01-29 · row 1
Holding and transaction disclosures are not merged.
1 source rowRow 1 · Balance 1,280,001.754 |
| Class I Common Shares of Beneficial InterestSEC Table I · non-derivative | IndirectFMR Capital Inc. | 86.107 |
Reported balance
Holding disclosure · report date 2024-01-29 · row 2
Holding and transaction disclosures are not merged.
1 source rowRow 2 · Balance 86.107 |
| Class I Common Shares of Beneficial InterestSEC Table I · non-derivative | IndirectFidelity Multi-Strategy Credit Fund | 352,359.548 |
Reported balance
Holding disclosure · report date 2024-01-29 · row 3
Holding and transaction disclosures are not merged.
1 source rowRow 3 · Balance 352,359.548 |
| Class S Common Shares of Beneficial InterestSEC Table I · non-derivative | IndirectFMR Capital Inc. | 397.521 |
Reported balance
Holding disclosure · report date 2024-01-29 · row 4
Holding and transaction disclosures are not merged.
1 source rowRow 4 · Balance 397.521 |
| Class D Common Shares of Beneficial InterestSEC Table I · non-derivative | IndirectFMR Capital Inc. | 397.917 |
Reported balance
Holding disclosure · report date 2024-01-29 · row 5
Holding and transaction disclosures are not merged.
1 source rowRow 5 · Balance 397.917 |
Flywire Corp
Report date May 28, 2021 · Filed June 02, 2021
Section 16 reporting ended · disclosed 2021-06-02. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | IndirectF-Prime Capital Partners Tech Fund LP | 4,183,071 |
Reported balance
After 2021-05-28 transaction · row 1
Holding and transaction disclosures are not merged.
1 source rowRow 1 · 2021-05-28 · Conversion · Acquired 4,183,071 · Balance 4,183,071 F1: On May 28, 2021 , in connection with the completion of the issuer's initial public offering, each share of Series A, B, C, B-1 NV, and B-1 Preferred Stock converted into 1 share of Common Stock. |
| Common StockSEC Table I · non-derivative | IndirectF-Prime Capital Partners Tech Fund LP | 5,328,597 |
Reported balance
After 2021-05-28 transaction · row 2
Holding and transaction disclosures are not merged.
1 source rowRow 2 · 2021-05-28 · Conversion · Acquired 1,145,526 · Balance 5,328,597 F1: On May 28, 2021 , in connection with the completion of the issuer's initial public offering, each share of Series A, B, C, B-1 NV, and B-1 Preferred Stock converted into 1 share of Common Stock. |
| Common StockSEC Table I · non-derivative | IndirectF-Prime Capital Partners Tech Fund LP | 6,829,032 |
Reported balance
After 2021-05-28 transaction · row 3
Holding and transaction disclosures are not merged.
1 source rowRow 3 · 2021-05-28 · Conversion · Acquired 1,500,435 · Balance 6,829,032 F1: On May 28, 2021 , in connection with the completion of the issuer's initial public offering, each share of Series A, B, C, B-1 NV, and B-1 Preferred Stock converted into 1 share of Common Stock. |
| Common StockSEC Table I · non-derivative | IndirectF-Prime Capital Partners Tech Fund LP | 7,249,056 |
Reported balance
After 2021-05-28 transaction · row 4
Holding and transaction disclosures are not merged.
1 source rowRow 4 · 2021-05-28 · Conversion · Acquired 420,024 · Balance 7,249,056 F1: On May 28, 2021 , in connection with the completion of the issuer's initial public offering, each share of Series A, B, C, B-1 NV, and B-1 Preferred Stock converted into 1 share of Common Stock. |
| Common StockSEC Table I · non-derivative | IndirectF-Prime Capital Partners Tech Fund LP | 7,268,490 |
Reported balance
After 2021-05-28 transaction · row 5
Holding and transaction disclosures are not merged.
1 source rowRow 5 · 2021-05-28 · Conversion · Acquired 19,434 · Balance 7,268,490 F1: On May 28, 2021 , in connection with the completion of the issuer's initial public offering, each share of Series A, B, C, B-1 NV, and B-1 Preferred Stock converted into 1 share of Common Stock. |
| Common StockSEC Table I · non-derivative | IndirectF-Prime Capital Partners Tech Fund LP | 7,460,328 |
Reported balance
Holding disclosure · report date 2021-05-28 · row 6
Holding and transaction disclosures are not merged.
1 source rowRow 6 · Balance 7,460,328 |
| Series B-1 Preferred StockSEC Table II · derivative / convertible security | IndirectF-Prime Capital Partners Tech Fund LP | 0 |
Reported balance
After 2021-05-28 transaction · row 7
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 7 · 2021-05-28 · Conversion · Disposed 4,183,071 · Balance 0 F1: On May 28, 2021 , in connection with the completion of the issuer's initial public offering, each share of Series A, B, C, B-1 NV, and B-1 Preferred Stock converted into 1 share of Common Stock. |
| Series B-1 NV Preferred StockSEC Table II · derivative / convertible security | IndirectF-Prime Capital Partners Tech Fund LP | 0 |
Reported balance
After 2021-05-28 transaction · row 8
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 8 · 2021-05-28 · Conversion · Disposed 1,145,526 · Balance 0 F1: On May 28, 2021 , in connection with the completion of the issuer's initial public offering, each share of Series A, B, C, B-1 NV, and B-1 Preferred Stock converted into 1 share of Common Stock. |
| Series C Preferred StockSEC Table II · derivative / convertible security | IndirectF-Prime Capital Partners Tech Fund LP | 0 |
Reported balance
After 2021-05-28 transaction · row 9
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 9 · 2021-05-28 · Conversion · Disposed 1,500,435 · Balance 0 F1: On May 28, 2021 , in connection with the completion of the issuer's initial public offering, each share of Series A, B, C, B-1 NV, and B-1 Preferred Stock converted into 1 share of Common Stock. |
| Series B Preferred StockSEC Table II · derivative / convertible security | IndirectF-Prime Capital Partners Tech Fund LP | 0 |
Reported balance
After 2021-05-28 transaction · row 10
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 10 · 2021-05-28 · Conversion · Disposed 420,024 · Balance 0 F1: On May 28, 2021 , in connection with the completion of the issuer's initial public offering, each share of Series A, B, C, B-1 NV, and B-1 Preferred Stock converted into 1 share of Common Stock. |
| Series A Preferred StockSEC Table II · derivative / convertible security | IndirectF-Prime Capital Partners Tech Fund LP | 0 |
Reported balance
After 2021-05-28 transaction · row 11
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 11 · 2021-05-28 · Conversion · Disposed 19,434 · Balance 0 F1: On May 28, 2021 , in connection with the completion of the issuer's initial public offering, each share of Series A, B, C, B-1 NV, and B-1 Preferred Stock converted into 1 share of Common Stock. |
Filing footnotes · ownership attribution and instrument terms
F1: On May 28, 2021 , in connection with the completion of the issuer's initial public offering, each share of Series A, B, C, B-1 NV, and B-1 Preferred Stock converted into 1 share of Common Stock.
KINETA, INC./DE
Report date March 13, 2017 · Filed March 15, 2017
Section 16 reporting ended · disclosed 2017-03-15. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | IndirectSee Footnote | 243,508 |
Reported balance
After 2017-03-13 transaction · row 1
Account identity is unresolved; indirect or unspecified ownership is not merged.
1 source rowRow 1 · 2017-03-13 · Sale · Disposed 25,000 · Balance 243,508 F2: The price reported for this transaction is the weighted average price of multiple trades at prices ranging from $12.21 to $13.18. FMR LLC hereby undertakes to provide upon request by the Commission staff, the issuer, or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. F1: By Impresa Fund III Limited Partnership (238,685 shares of Common Stock) and F-Prime Inc. (4,823 shares of Common Stock). Impresa Fund III Limited Partnership is solely managed by Impresa Management LLC, its general partner and investment manager. Impresa Management LLC is owned, directly or indirectly, by various shareholders and employees of FMR LLC, including certain members of the Johnson family. F-Prime Inc. is a wholly-owned subsidiary of FMR LLC. |
Filing footnotes · ownership attribution and instrument terms
F1: By Impresa Fund III Limited Partnership (238,685 shares of Common Stock) and F-Prime Inc. (4,823 shares of Common Stock). Impresa Fund III Limited Partnership is solely managed by Impresa Management LLC, its general partner and investment manager. Impresa Management LLC is owned, directly or indirectly, by various shareholders and employees of FMR LLC, including certain members of the Johnson family. F-Prime Inc. is a wholly-owned subsidiary of FMR LLC.
F2: The price reported for this transaction is the weighted average price of multiple trades at prices ranging from $12.21 to $13.18. FMR LLC hereby undertakes to provide upon request by the Commission staff, the issuer, or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
Mersana Therapeutics, Inc.
Report date July 03, 2017 · Filed July 06, 2017
Section 16 reporting ended · disclosed 2017-07-06. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | IndirectF-Prime Capital Partners Healthcare Fund III LP | 718,375 |
Reported balance
After 2017-07-03 transaction · row 3
Account identity is unresolved; indirect or unspecified ownership is not merged.
1 source rowRow 3 · 2017-07-03 · Conversion · Acquired 718,375 · Balance 718,375 F1: On July 3, 2017, in connection with the completion of the issuer's initial public offering, each share of Convertible Preferred Stock converted into one share of Common Stock. |
| Common StockSEC Table I · non-derivative | IndirectccF-Prime Capital Partners Healthcare Fund III LP | 1,329,981 |
Reported balance
After 2017-07-03 transaction · row 4
Account identity is unresolved; indirect or unspecified ownership is not merged.
1 source rowRow 4 · 2017-07-03 · Conversion · Acquired 611,606 · Balance 1,329,981 F1: On July 3, 2017, in connection with the completion of the issuer's initial public offering, each share of Convertible Preferred Stock converted into one share of Common Stock. |
| Series A-1 Convertible Preferred StockSEC Table II · derivative / convertible security | IndirectF-Prime Capital Partners Healthcare Fund III LP | 0 |
Reported balance
After 2017-07-03 transaction · row 6
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 6 · 2017-07-03 · Conversion · Disposed 718,375 · Balance 0 F1: On July 3, 2017, in connection with the completion of the issuer's initial public offering, each share of Convertible Preferred Stock converted into one share of Common Stock. |
| Series B-1 Convertible Preferred StockSEC Table II · derivative / convertible security | IndirectF-Prime Capital Partners Healthcare Fund III LP | 0 |
Reported balance
After 2017-07-03 transaction · row 7
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 7 · 2017-07-03 · Conversion · Disposed 611,606 · Balance 0 F1: On July 3, 2017, in connection with the completion of the issuer's initial public offering, each share of Convertible Preferred Stock converted into one share of Common Stock. |
| Common StockSEC Table I · non-derivative | IndirectF-Prime Capital Partners Healthcare Fund LP | 383,357 |
Reported balance
Holding disclosure · report date 2017-07-03 · row 1
Holding and transaction disclosures are not merged.
1 source rowRow 1 · Balance 383,357 |
| Common StockSEC Table I · non-derivative | IndirectF-Prime Capital Partners HC Principals Fund LP | 2,597 |
Reported balance
Holding disclosure · report date 2017-07-03 · row 2
Holding and transaction disclosures are not merged.
1 source rowRow 2 · Balance 2,597 |
| WarrantSEC Table II · derivative / convertible security · Conversion / exercise price $0.05 · Expires 2023-09-27 | IndirectF-Prime Capital Partners Healthcare Fund III LP | 19,126 |
Reported balance
Holding disclosure · report date 2017-07-03 · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · Balance 19,126 |
Filing footnotes · ownership attribution and instrument terms
F1: On July 3, 2017, in connection with the completion of the issuer's initial public offering, each share of Convertible Preferred Stock converted into one share of Common Stock.
Metsera, Inc.
Report date November 13, 2025 · Filed November 17, 2025
Section 16 reporting ended · disclosed 2025-11-17. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | IndirectF-Prime Inc. | 0 |
Reported balance
After 2025-11-13 transaction · row 1
Account identity is unresolved; indirect or unspecified ownership is not merged.
1 source rowRow 1 · 2025-11-13 · Other · Disposed 3,010 · Balance 0 F1: Pursuant to the Agreement and Plan of Merger dated September 21, 2025, as amended on November 7, 2025 (the "Merger Agreement"), by and among Metsera, Inc. (the "Company"), Pfizer Inc., a Delaware corporation ("Parent"), and Mayfair Merger Sub, Inc., a Delaware corporation and a wholly owned subsidiary of the Parent (the "Merger Sub"), the Merger Sub merged with and into the Company, with the Company continuing as the surviving corporation and a wholly owned subsidiary of the Parent (the "Merger"). At the Effective Time of the Merger (as defined in the Merger Agreement), each issued and outstanding share of common stock, par value $0.00001 per share of the Company (the "Common Stock") was converted automatically into the right to receive (i) cash in an amount equal to $65.60 per share without interest (the "Closing Amount"), F2: (Continued from footnote 1) net of all applicable withholding taxes, plus (ii) one contractual contingent value right representing the right to receive contingent payments (a "CVR") in cash, without interest, upon the achievement of certain specified milestones, in accordance with the terms and conditions of the contingent value rights agreement entered into by the Parent and Equiniti Trust Company, LLC, dated November 13, 2025 (collectively, the "Merger Consideration"). |
| Common StockSEC Table I · non-derivative | IndirectShares held by persons and entities whose shares are subject to reporting by the undersigned. | 0 |
Reported balance
After 2025-11-13 transaction · row 2
Account identity is unresolved; indirect or unspecified ownership is not merged.
1 source rowRow 2 · 2025-11-13 · Other · Disposed 2,230,450 · Balance 0 F1: Pursuant to the Agreement and Plan of Merger dated September 21, 2025, as amended on November 7, 2025 (the "Merger Agreement"), by and among Metsera, Inc. (the "Company"), Pfizer Inc., a Delaware corporation ("Parent"), and Mayfair Merger Sub, Inc., a Delaware corporation and a wholly owned subsidiary of the Parent (the "Merger Sub"), the Merger Sub merged with and into the Company, with the Company continuing as the surviving corporation and a wholly owned subsidiary of the Parent (the "Merger"). At the Effective Time of the Merger (as defined in the Merger Agreement), each issued and outstanding share of common stock, par value $0.00001 per share of the Company (the "Common Stock") was converted automatically into the right to receive (i) cash in an amount equal to $65.60 per share without interest (the "Closing Amount"), F2: (Continued from footnote 1) net of all applicable withholding taxes, plus (ii) one contractual contingent value right representing the right to receive contingent payments (a "CVR") in cash, without interest, upon the achievement of certain specified milestones, in accordance with the terms and conditions of the contingent value rights agreement entered into by the Parent and Equiniti Trust Company, LLC, dated November 13, 2025 (collectively, the "Merger Consideration"). |
Filing footnotes · ownership attribution and instrument terms
F1: Pursuant to the Agreement and Plan of Merger dated September 21, 2025, as amended on November 7, 2025 (the "Merger Agreement"), by and among Metsera, Inc. (the "Company"), Pfizer Inc., a Delaware corporation ("Parent"), and Mayfair Merger Sub, Inc., a Delaware corporation and a wholly owned subsidiary of the Parent (the "Merger Sub"), the Merger Sub merged with and into the Company, with the Company continuing as the surviving corporation and a wholly owned subsidiary of the Parent (the "Merger"). At the Effective Time of the Merger (as defined in the Merger Agreement), each issued and outstanding share of common stock, par value $0.00001 per share of the Company (the "Common Stock") was converted automatically into the right to receive (i) cash in an amount equal to $65.60 per share without interest (the "Closing Amount"),
F2: (Continued from footnote 1) net of all applicable withholding taxes, plus (ii) one contractual contingent value right representing the right to receive contingent payments (a "CVR") in cash, without interest, upon the achievement of certain specified milestones, in accordance with the terms and conditions of the contingent value rights agreement entered into by the Parent and Equiniti Trust Company, LLC, dated November 13, 2025 (collectively, the "Merger Consideration").
Neumora Therapeutics, Inc.
Report date September 19, 2023 · Filed September 21, 2023
Section 16 reporting ended · disclosed 2023-09-21. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | IndirectF-Prime Capital Partners Life Sciences Fund VII LP | 5,387,375 |
Reported balance
After 2023-09-19 transaction · row 2
Holding and transaction disclosures are not merged.
1 source rowRow 2 · 2023-09-19 · Conversion · Acquired 3,475,646 · Balance 5,387,375 F1: On September 19, 2023, in connection with the completion of the issuer's initial public offering, each share of Series A-2 and B Preferred Shares converted on a 1-for-1 basis into shares of Common Stock. |
| Common StockSEC Table I · non-derivative | IndirectF-Prime Capital Partners Life Sciences Fund VII LP | 5,472,340 |
Reported balance
After 2023-09-19 transaction · row 3
Holding and transaction disclosures are not merged.
1 source rowRow 3 · 2023-09-19 · Conversion · Acquired 84,965 · Balance 5,472,340 F1: On September 19, 2023, in connection with the completion of the issuer's initial public offering, each share of Series A-2 and B Preferred Shares converted on a 1-for-1 basis into shares of Common Stock. |
| Common StockSEC Table I · non-derivative | IndirectF-Prime Capital Partners Life Sciences Fund VII LP | 1,911,729 |
Reported balance
Holding disclosure · report date 2023-09-19 · row 1
Holding and transaction disclosures are not merged.
1 source rowRow 1 · Balance 1,911,729 |
| Common StockSEC Table I · non-derivative | IndirectF-Prime Inc. | 63,724 |
Reported balance
After 2023-09-19 transaction · row 4
Account identity is unresolved; indirect or unspecified ownership is not merged.
1 source rowRow 4 · 2023-09-19 · Conversion · Acquired 63,724 · Balance 63,724 F1: On September 19, 2023, in connection with the completion of the issuer's initial public offering, each share of Series A-2 and B Preferred Shares converted on a 1-for-1 basis into shares of Common Stock. |
| Common StockSEC Table I · non-derivative | IndirectFBRI LLC | 88,289 |
Reported balance
After 2023-09-19 transaction · row 5
Account identity is unresolved; indirect or unspecified ownership is not merged.
1 source rowRow 5 · 2023-09-19 · Conversion · Acquired 88,289 · Balance 88,289 F1: On September 19, 2023, in connection with the completion of the issuer's initial public offering, each share of Series A-2 and B Preferred Shares converted on a 1-for-1 basis into shares of Common Stock. |
| Series A-2 Preferred StockSEC Table II · derivative / convertible security | IndirectF-Prime Inc. | 0 |
Reported balance
After 2023-09-19 transaction · row 6
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 6 · 2023-09-19 · Conversion · Disposed 63,724 · Balance 0 F1: On September 19, 2023, in connection with the completion of the issuer's initial public offering, each share of Series A-2 and B Preferred Shares converted on a 1-for-1 basis into shares of Common Stock. |
| Series A-2 Preferred StockSEC Table II · derivative / convertible security | IndirectF-Prime Capital Partners Life Sciences Fund VII LP | 0 |
Reported balance
After 2023-09-19 transaction · row 7
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 7 · 2023-09-19 · Conversion · Disposed 3,475,646 · Balance 0 F1: On September 19, 2023, in connection with the completion of the issuer's initial public offering, each share of Series A-2 and B Preferred Shares converted on a 1-for-1 basis into shares of Common Stock. |
| Series B Preferred StockSEC Table II · derivative / convertible security | IndirectF-Prime Capital Partners Life Sciences Fund VII LP | 0 |
Reported balance
After 2023-09-19 transaction · row 8
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 8 · 2023-09-19 · Conversion · Disposed 84,965 · Balance 0 F1: On September 19, 2023, in connection with the completion of the issuer's initial public offering, each share of Series A-2 and B Preferred Shares converted on a 1-for-1 basis into shares of Common Stock. |
| Series A-2 Preferred StockSEC Table II · derivative / convertible security | IndirectFBRI LLC | 0 |
Reported balance
After 2023-09-19 transaction · row 9
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 9 · 2023-09-19 · Conversion · Disposed 88,289 · Balance 0 F1: On September 19, 2023, in connection with the completion of the issuer's initial public offering, each share of Series A-2 and B Preferred Shares converted on a 1-for-1 basis into shares of Common Stock. |
Filing footnotes · ownership attribution and instrument terms
F1: On September 19, 2023, in connection with the completion of the issuer's initial public offering, each share of Series A-2 and B Preferred Shares converted on a 1-for-1 basis into shares of Common Stock.
Orchard Therapeutics plc
Report date March 09, 2021 · Filed March 10, 2021
Section 16 reporting ended · disclosed 2021-03-10. Current position is not established by this disclosure.
No balance rows disclosed in this filing.
PRECISION BIOSCIENCES INC
Report date April 01, 2019 · Filed April 03, 2019
Section 16 reporting ended · disclosed 2019-04-03. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | IndirectBy F-Prime Capital Partners Healthcare Fund IV LP | 3,279,170 |
Reported balance
After 2019-04-01 transaction · row 1
Account identity is unresolved; indirect or unspecified ownership is not merged.
1 source rowRow 1 · 2019-04-01 · Conversion · Acquired 3,279,170 · Balance 3,279,170 F1: On April 1, 2019, in connection with the completion of the issuer's initial public offering, each 2.134686 shares of Series A Preferred Stock and Series B Preferred Stock converted into 1 share of Common Stock. |
| Common StockSEC Table I · non-derivative | IndirectBy F-Prime Capital Partners Healthcare Fund IV LP | 3,688,248 |
Reported balance
After 2019-04-01 transaction · row 2
Account identity is unresolved; indirect or unspecified ownership is not merged.
1 source rowRow 2 · 2019-04-01 · Conversion · Acquired 409,078 · Balance 3,688,248 F1: On April 1, 2019, in connection with the completion of the issuer's initial public offering, each 2.134686 shares of Series A Preferred Stock and Series B Preferred Stock converted into 1 share of Common Stock. |
| Common StockSEC Table I · non-derivative | IndirectBy F-Prime Capital Partners Healthcare Fund IV LP | 3,738,248 |
Reported balance
After 2019-04-01 transaction · row 3
Account identity is unresolved; indirect or unspecified ownership is not merged.
1 source rowRow 3 · 2019-04-01 · Purchase · Acquired 50,000 · Balance 3,738,248 |
| Series A Preferred StockSEC Table II · derivative / convertible security | IndirectBy F-Prime Capital Partners Healthcare Fund IV LP | 0 |
Reported balance
After 2019-04-01 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2019-04-01 · Conversion · Disposed 7,000,000 · Balance 0 F1: On April 1, 2019, in connection with the completion of the issuer's initial public offering, each 2.134686 shares of Series A Preferred Stock and Series B Preferred Stock converted into 1 share of Common Stock. |
| Series B Preferred StockSEC Table II · derivative / convertible security | IndirectBy F-Prime Capital Partners Healthcare Fund IV LP | 0 |
Reported balance
After 2019-04-01 transaction · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · 2019-04-01 · Conversion · Disposed 873,253 · Balance 0 F1: On April 1, 2019, in connection with the completion of the issuer's initial public offering, each 2.134686 shares of Series A Preferred Stock and Series B Preferred Stock converted into 1 share of Common Stock. |
Filing footnotes · ownership attribution and instrument terms
F1: On April 1, 2019, in connection with the completion of the issuer's initial public offering, each 2.134686 shares of Series A Preferred Stock and Series B Preferred Stock converted into 1 share of Common Stock.
Prime Medicine, Inc.
Report date October 24, 2022 · Filed October 26, 2022
Section 16 reporting ended · disclosed 2022-10-26. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | IndirectF-Prime Capital Partners Life Sciences Fund VI LP | 4,124,375 |
Reported balance
After 2022-10-24 transaction · row 1
Account identity is unresolved; indirect or unspecified ownership is not merged.
1 source rowRow 1 · 2022-10-24 · Conversion · Acquired 4,124,375 · Balance 4,124,375 F1: On October 24, 2022, in connection with the completion of the issuer's initial public offering, each share of Series A and B Preferred Stock converted on a 1-for-1 basis into shares of Common Stock. |
| Common StockSEC Table I · non-derivative | IndirectF-Prime Capital Partners Life Sciences Advisors Fund VI LP | 98,967 |
Reported balance
After 2022-10-24 transaction · row 2
Account identity is unresolved; indirect or unspecified ownership is not merged.
1 source rowRow 2 · 2022-10-24 · Conversion · Acquired 98,967 · Balance 98,967 F1: On October 24, 2022, in connection with the completion of the issuer's initial public offering, each share of Series A and B Preferred Stock converted on a 1-for-1 basis into shares of Common Stock. |
| Common StockSEC Table I · non-derivative | IndirectF-Prime Capital Partners Life Sciences Advisors Fund VI LP | 109,982 |
Reported balance
After 2022-10-24 transaction · row 3
Account identity is unresolved; indirect or unspecified ownership is not merged.
1 source rowRow 3 · 2022-10-24 · Conversion · Acquired 11,015 · Balance 109,982 F1: On October 24, 2022, in connection with the completion of the issuer's initial public offering, each share of Series A and B Preferred Stock converted on a 1-for-1 basis into shares of Common Stock. |
| Common StockSEC Table I · non-derivative | IndirectEntity managed by Impresa Management LLC whose shares are subject to reporting by the Undersigned | 3,805,080 |
Reported balance
After 2022-10-24 transaction · row 4
Account identity is unresolved; indirect or unspecified ownership is not merged.
1 source rowRow 4 · 2022-10-24 · Conversion · Acquired 3,805,080 · Balance 3,805,080 F1: On October 24, 2022, in connection with the completion of the issuer's initial public offering, each share of Series A and B Preferred Stock converted on a 1-for-1 basis into shares of Common Stock. |
| Common StockSEC Table I · non-derivative | IndirectEntity managed by Impresa Management LLC whose shares are subject to reporting by the Undersigned | 4,228,589 |
Reported balance
After 2022-10-24 transaction · row 5
Account identity is unresolved; indirect or unspecified ownership is not merged.
1 source rowRow 5 · 2022-10-24 · Conversion · Acquired 423,509 · Balance 4,228,589 F1: On October 24, 2022, in connection with the completion of the issuer's initial public offering, each share of Series A and B Preferred Stock converted on a 1-for-1 basis into shares of Common Stock. |
| Series A Convertible Preferred StockSEC Table II · derivative / convertible security | IndirectF-Prime Capital Partners Life Sciences Fund VI LP | 0 |
Reported balance
After 2022-10-24 transaction · row 6
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 6 · 2022-10-24 · Conversion · Disposed 4,124,375 · Balance 0 F1: On October 24, 2022, in connection with the completion of the issuer's initial public offering, each share of Series A and B Preferred Stock converted on a 1-for-1 basis into shares of Common Stock. |
| Series A Convertible Preferred StockSEC Table II · derivative / convertible security | IndirectF-Prime Capital Partners Life Sciences Advisors Fund VI LP | 0 |
Reported balance
After 2022-10-24 transaction · row 7
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 7 · 2022-10-24 · Conversion · Disposed 98,967 · Balance 0 F1: On October 24, 2022, in connection with the completion of the issuer's initial public offering, each share of Series A and B Preferred Stock converted on a 1-for-1 basis into shares of Common Stock. |
| Series B Convertible Preferred StockSEC Table II · derivative / convertible security | IndirectF-Prime Capital Partners Life Sciences Advisors Fund VI LP | 0 |
Reported balance
After 2022-10-24 transaction · row 8
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 8 · 2022-10-24 · Conversion · Disposed 11,015 · Balance 0 F1: On October 24, 2022, in connection with the completion of the issuer's initial public offering, each share of Series A and B Preferred Stock converted on a 1-for-1 basis into shares of Common Stock. |
| Series A Convertible Preferred StockSEC Table II · derivative / convertible security | IndirectEntity managed by Impresa Management LLC whose shares are subject to reporting by the Undersigned | 0 |
Reported balance
After 2022-10-24 transaction · row 9
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 9 · 2022-10-24 · Conversion · Disposed 3,805,080 · Balance 0 F1: On October 24, 2022, in connection with the completion of the issuer's initial public offering, each share of Series A and B Preferred Stock converted on a 1-for-1 basis into shares of Common Stock. |
| Series B Convertible Preferred StockSEC Table II · derivative / convertible security | IndirectEntity managed by Impresa Management LLC whose shares are subject to reporting by the Undersigned | 0 |
Reported balance
After 2022-10-24 transaction · row 10
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 10 · 2022-10-24 · Conversion · Disposed 423,509 · Balance 0 F1: On October 24, 2022, in connection with the completion of the issuer's initial public offering, each share of Series A and B Preferred Stock converted on a 1-for-1 basis into shares of Common Stock. |
Filing footnotes · ownership attribution and instrument terms
F1: On October 24, 2022, in connection with the completion of the issuer's initial public offering, each share of Series A and B Preferred Stock converted on a 1-for-1 basis into shares of Common Stock.
Surface Oncology, Inc.
Report date July 25, 2018 · Filed July 27, 2018
Section 16 reporting ended · disclosed 2018-07-27. Current position is not established by this disclosure.
No balance rows disclosed in this filing.
Toast, Inc.
Report date November 09, 2021 · Filed November 12, 2021
Section 16 reporting ended · disclosed 2021-11-12. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Class B Common StockSEC Table II · derivative / convertible security | IndirectF-Prime Capital Partners Tech Fund LP | 6,703,780 |
Reported balance
Holding disclosure · report date 2021-11-09 · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · Balance 6,703,780 F1: The Class B Common Stock shares are convertible on a 1-for-1 basis into the number of shares of Class A Common Stock as shown in column 3 at any time at the holder's election, and after the closing of the Issuer's initial public offering without payment or further consideration, and have no expiration date. |
Filing footnotes · ownership attribution and instrument terms
F1: The Class B Common Stock shares are convertible on a 1-for-1 basis into the number of shares of Class A Common Stock as shown in column 3 at any time at the holder's election, and after the closing of the Issuer's initial public offering without payment or further consideration, and have no expiration date.
Turnstone Biologics Corp.
Report date January 09, 2024 · Filed January 11, 2024
Section 16 reporting ended · disclosed 2024-01-11. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | IndirectF-Prime Capital Partners Healthcare Fund V LP | 832,652 |
Reported balance
Holding disclosure · report date 2024-01-09 · row 1
Holding and transaction disclosures are not merged.
1 source rowRow 1 · Balance 832,652 |
| Common StockSEC Table I · non-derivative | IndirectImpresa Fund III Limited Partnership | 296,396 |
Reported balance
Holding disclosure · report date 2024-01-09 · row 2
Holding and transaction disclosures are not merged.
1 source rowRow 2 · Balance 296,396 |
| Common StockSEC Table I · non-derivative | IndirectF-Prime Capital Partners Healthcare Advisors Fund V LP | 4,939 |
Reported balance
Holding disclosure · report date 2024-01-09 · row 3
Holding and transaction disclosures are not merged.
1 source rowRow 3 · Balance 4,939 |
Verve Therapeutics, Inc.
Report date July 26, 2022 · Filed July 28, 2022
Section 16 reporting ended · disclosed 2022-07-28. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | IndirectF-Prime Capital Partners Healthcare Fund V LP | 570,729 |
Reported balance
Holding disclosure · report date 2022-07-26 · row 1
Holding and transaction disclosures are not merged.
1 source rowRow 1 · Balance 570,729 |
ViewRay, Inc.
Report date August 08, 2018 · Filed August 10, 2018
Section 16 reporting ended · disclosed 2018-08-10. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | IndirectF-Prime Capital Partners Healthcare Fund II LP | 604,736 |
Reported balance
After 2018-08-08 transaction · row 1
Account identity is unresolved; indirect or unspecified ownership is not merged.
1 source rowRow 1 · 2018-08-08 · Sale · Disposed 200,000 · Balance 604,736 F3: The price reported for this transaction is the weighted average price of multiple trades at prices ranging from $10.00 to $10.07. FMR LLC hereby undertakes to provide upon request by the Commission staff, the issuer, or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. F1: The general partner of F-Prime Capital Partners Healthcare Fund II LP is F-Prime Capital Partners Healthcare Advisors Fund II LP. F-Prime Capital Partners Healthcare Advisors Fund II LP is solely managed by Impresa Management LLC, its general partner and investment manager. Impresa Management LLC is owned, directly or indirectly, by various shareholders and employees of FMR LLC, including certain members of the Johnson family. |
| Common StockSEC Table I · non-derivative | IndirectFIMM, LLC | 1,620 |
Reported balance
Holding disclosure · report date 2018-08-08 · row 2
Holding and transaction disclosures are not merged.
1 source rowRow 2 · Balance 1,620 F2: FIMM, LLC is an indirect, wholly-owned subsidiary of FMR LLC. |
Filing footnotes · ownership attribution and instrument terms
F1: The general partner of F-Prime Capital Partners Healthcare Fund II LP is F-Prime Capital Partners Healthcare Advisors Fund II LP. F-Prime Capital Partners Healthcare Advisors Fund II LP is solely managed by Impresa Management LLC, its general partner and investment manager. Impresa Management LLC is owned, directly or indirectly, by various shareholders and employees of FMR LLC, including certain members of the Johnson family.
F2: FIMM, LLC is an indirect, wholly-owned subsidiary of FMR LLC.
F3: The price reported for this transaction is the weighted average price of multiple trades at prices ranging from $10.00 to $10.07. FMR LLC hereby undertakes to provide upon request by the Commission staff, the issuer, or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
Xilio Therapeutics, Inc.
Report date October 26, 2021 · Filed October 28, 2021
Section 16 reporting ended · disclosed 2021-10-28. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | IndirectF-Prime Capital Partners Healthcare Fund IV LP | 815,788 |
Reported balance
After 2021-10-26 transaction · row 2
Holding and transaction disclosures are not merged.
1 source rowRow 2 · 2021-10-26 · Conversion · Acquired 789,473 · Balance 815,788 F1: On October 26, 2021, in connection with the completion of the issuer's initial public offering, each share of Series A, A-1, and B Preferred Stock converted on a 1-for-9.5 basis into shares of Common Stock. |
| Common StockSEC Table I · non-derivative | IndirectF-Prime Capital Partners Healthcare Fund IV LP | 1,502,287 |
Reported balance
After 2021-10-26 transaction · row 3
Holding and transaction disclosures are not merged.
1 source rowRow 3 · 2021-10-26 · Conversion · Acquired 686,499 · Balance 1,502,287 F1: On October 26, 2021, in connection with the completion of the issuer's initial public offering, each share of Series A, A-1, and B Preferred Stock converted on a 1-for-9.5 basis into shares of Common Stock. |
| Common StockSEC Table I · non-derivative | IndirectF-Prime Capital Partners Healthcare Fund IV LP | 1,530,990 |
Reported balance
After 2021-10-26 transaction · row 4
Holding and transaction disclosures are not merged.
1 source rowRow 4 · 2021-10-26 · Conversion · Acquired 28,703 · Balance 1,530,990 F1: On October 26, 2021, in connection with the completion of the issuer's initial public offering, each share of Series A, A-1, and B Preferred Stock converted on a 1-for-9.5 basis into shares of Common Stock. |
| Common StockSEC Table I · non-derivative | IndirectF-Prime Capital Partners Healthcare Fund IV LP | 26,315 |
Reported balance
Holding disclosure · report date 2021-10-26 · row 1
Holding and transaction disclosures are not merged.
1 source rowRow 1 · Balance 26,315 |
| Common StockSEC Table I · non-derivative | IndirectImpresa Fund III Limited Partnership | 372,215 |
Reported balance
After 2021-10-26 transaction · row 5
Account identity is unresolved; indirect or unspecified ownership is not merged.
1 source rowRow 5 · 2021-10-26 · Conversion · Acquired 372,215 · Balance 372,215 F1: On October 26, 2021, in connection with the completion of the issuer's initial public offering, each share of Series A, A-1, and B Preferred Stock converted on a 1-for-9.5 basis into shares of Common Stock. |
| Common StockSEC Table I · non-derivative | IndirectF-Prime Capital Partners Healthcare Advisors Fund IV LP | 4,465 |
Reported balance
After 2021-10-26 transaction · row 6
Account identity is unresolved; indirect or unspecified ownership is not merged.
1 source rowRow 6 · 2021-10-26 · Conversion · Acquired 4,465 · Balance 4,465 F1: On October 26, 2021, in connection with the completion of the issuer's initial public offering, each share of Series A, A-1, and B Preferred Stock converted on a 1-for-9.5 basis into shares of Common Stock. |
| Series A Preferred StockSEC Table II · derivative / convertible security | IndirectF-Prime Capital Partners Healthcare Fund IV LP | 0 |
Reported balance
After 2021-10-26 transaction · row 7
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 7 · 2021-10-26 · Conversion · Disposed 7,500,000 · Balance 0 F1: On October 26, 2021, in connection with the completion of the issuer's initial public offering, each share of Series A, A-1, and B Preferred Stock converted on a 1-for-9.5 basis into shares of Common Stock. |
| Series A-1 Preferred StockSEC Table II · derivative / convertible security | IndirectF-Prime Capital Partners Healthcare Fund IV LP | 0 |
Reported balance
After 2021-10-26 transaction · row 8
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 8 · 2021-10-26 · Conversion · Disposed 6,521,739 · Balance 0 F1: On October 26, 2021, in connection with the completion of the issuer's initial public offering, each share of Series A, A-1, and B Preferred Stock converted on a 1-for-9.5 basis into shares of Common Stock. |
| Series B Preferred StockSEC Table II · derivative / convertible security | IndirectF-Prime Capital Partners Healthcare Fund IV LP | 0 |
Reported balance
After 2021-10-26 transaction · row 9
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 9 · 2021-10-26 · Conversion · Disposed 272,687 · Balance 0 F1: On October 26, 2021, in connection with the completion of the issuer's initial public offering, each share of Series A, A-1, and B Preferred Stock converted on a 1-for-9.5 basis into shares of Common Stock. |
| Series B Preferred StockSEC Table II · derivative / convertible security | IndirectImpresa Fund III Limited Partnership | 0 |
Reported balance
After 2021-10-26 transaction · row 10
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 10 · 2021-10-26 · Conversion · Disposed 3,536,046 · Balance 0 F1: On October 26, 2021, in connection with the completion of the issuer's initial public offering, each share of Series A, A-1, and B Preferred Stock converted on a 1-for-9.5 basis into shares of Common Stock. |
| Series B Preferred StockSEC Table II · derivative / convertible security | IndirectF-Prime Capital Partners Healthcare Advisors Fund IV LP | 0 |
Reported balance
After 2021-10-26 transaction · row 11
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 11 · 2021-10-26 · Conversion · Disposed 42,421 · Balance 0 F1: On October 26, 2021, in connection with the completion of the issuer's initial public offering, each share of Series A, A-1, and B Preferred Stock converted on a 1-for-9.5 basis into shares of Common Stock. |
Filing footnotes · ownership attribution and instrument terms
F1: On October 26, 2021, in connection with the completion of the issuer's initial public offering, each share of Series A, A-1, and B Preferred Stock converted on a 1-for-9.5 basis into shares of Common Stock.
Yarrow Bioscience, Inc.
Report date January 29, 2018 · Filed August 10, 2018 · Amendment
Section 16 reporting ended · disclosed 2018-08-10. Current position is not established by this disclosure.
Amendment: balances below belong to this corrected disclosure, not necessarily a complete replacement of earlier positions.
No balance rows disclosed in this filing.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| March 07, 2017 Filed Mar 8, 2017 20:33 UTC | KINETA, INC./DE PTI · Entity 77778 | SaleCommon Stock | 4,897 | $13.59 | $66,550.23 |
DisclosureSEC source: 0000315066-17-002193 · primary_doc.xml · nonDerivative · entry 3 FMR LLC · CIK 0000315066 · 10% owner · See Remark 1 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 322,808 F4 · price: The price reported for this transaction is the weighted average price of multiple trades at prices ranging from $13.40 to $14.01. FMR LLC hereby undertakes to provide upon request by the Commission staff, the issuer, or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. F1 · ownership.nature: By Impresa Fund III Limited Partnership (317,985 shares of Common Stock) and F-Prime Inc. (4,823 shares of Common Stock). Impresa Fund III Limited Partnership is solely managed by Impresa Management LLC, its general partner and investment manager. Impresa Management LLC is owned, directly or indirectly, by various shareholders and employees of FMR LLC, including certain members of the Johnson family. F-Prime Inc. is a wholly-owned subsidiary of FMR LLC. Read SEC document |
| March 07, 2017 Filed Mar 8, 2017 20:33 UTC | KINETA, INC./DE PTI · Entity 77778 | SaleCommon Stock | 30,103 | $12.67 | $381,405.01 |
DisclosureSEC source: 0000315066-17-002193 · primary_doc.xml · nonDerivative · entry 2 FMR LLC · CIK 0000315066 · 10% owner · See Remark 1 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 327,705 F3 · price: The price reported for this transaction is the weighted average price of multiple trades at prices ranging from $12.40 to $13.38. FMR LLC hereby undertakes to provide upon request by the Commission staff, the issuer, or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. F1 · ownership.nature: By Impresa Fund III Limited Partnership (317,985 shares of Common Stock) and F-Prime Inc. (4,823 shares of Common Stock). Impresa Fund III Limited Partnership is solely managed by Impresa Management LLC, its general partner and investment manager. Impresa Management LLC is owned, directly or indirectly, by various shareholders and employees of FMR LLC, including certain members of the Johnson family. F-Prime Inc. is a wholly-owned subsidiary of FMR LLC. Read SEC document |
| March 06, 2017 Filed Mar 8, 2017 20:33 UTC | KINETA, INC./DE PTI · Entity 77778 | SaleCommon Stock | 25,000 | $13.31 | $332,750.00 |
DisclosureSEC source: 0000315066-17-002193 · primary_doc.xml · nonDerivative · entry 1 FMR LLC · CIK 0000315066 · 10% owner · See Remark 1 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 357,808 F2 · price: The price reported for this transaction is the weighted average price of multiple trades at prices ranging from $13.00 to $13.77. FMR LLC hereby undertakes to provide upon request by the Commission staff, the issuer, or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. F1 · ownership.nature: By Impresa Fund III Limited Partnership (317,985 shares of Common Stock) and F-Prime Inc. (4,823 shares of Common Stock). Impresa Fund III Limited Partnership is solely managed by Impresa Management LLC, its general partner and investment manager. Impresa Management LLC is owned, directly or indirectly, by various shareholders and employees of FMR LLC, including certain members of the Johnson family. F-Prime Inc. is a wholly-owned subsidiary of FMR LLC. Read SEC document |
| March 03, 2017 Filed Mar 6, 2017 23:05 UTC | KINETA, INC./DE PTI · Entity 77778 | SaleCommon Stock | 20,000 | $13.63 | $272,600.00 |
DisclosureSEC source: 0000315066-17-002192 · primary_doc.xml · nonDerivative · entry 3 FMR LLC · CIK 0000315066 · 10% owner · See Remark 1 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 382,808 F4 · price: The price reported for this transaction is the weighted average price of multiple trades at prices ranging from $13.43 to $14.23. FMR LLC hereby undertakes to provide upon request by the Commission staff, the issuer, or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. F1 · ownership.nature: By Impresa Fund III Limited Partnership (377,985 shares of Common Stock) and F-Prime Inc. (4,823 shares of Common Stock). Impresa Fund III Limited Partnership is solely managed by Impresa Management LLC, its general partner and investment manager. Impresa Management LLC is owned, directly or indirectly, by various shareholders and employees of FMR LLC, including certain members of the Johnson family. F-Prime Inc. is a wholly-owned subsidiary of FMR LLC. Read SEC document |
| March 02, 2017 Filed Mar 6, 2017 23:05 UTC | KINETA, INC./DE PTI · Entity 77778 | SaleCommon Stock | 4,500 | $14.58 | $65,610.00 |
DisclosureSEC source: 0000315066-17-002192 · primary_doc.xml · nonDerivative · entry 2 FMR LLC · CIK 0000315066 · 10% owner · See Remark 1 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 402,808 F3 · price: The price reported for this transaction is the weighted average price of multiple trades at prices ranging from $14.47 to $14.72. FMR LLC hereby undertakes to provide upon request by the Commission staff, the issuer, or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. F1 · ownership.nature: By Impresa Fund III Limited Partnership (377,985 shares of Common Stock) and F-Prime Inc. (4,823 shares of Common Stock). Impresa Fund III Limited Partnership is solely managed by Impresa Management LLC, its general partner and investment manager. Impresa Management LLC is owned, directly or indirectly, by various shareholders and employees of FMR LLC, including certain members of the Johnson family. F-Prime Inc. is a wholly-owned subsidiary of FMR LLC. Read SEC document |
| March 02, 2017 Filed Mar 6, 2017 23:05 UTC | KINETA, INC./DE PTI · Entity 77778 | SaleCommon Stock | 20,500 | $14.03 | $287,615.00 |
DisclosureSEC source: 0000315066-17-002192 · primary_doc.xml · nonDerivative · entry 1 FMR LLC · CIK 0000315066 · 10% owner · See Remark 1 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 407,308 F2 · price: The price reported for this transaction is the weighted average price of multiple trades at prices ranging from $13.47 to $14.46. FMR LLC hereby undertakes to provide upon request by the Commission staff, the issuer, or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. F1 · ownership.nature: By Impresa Fund III Limited Partnership (377,985 shares of Common Stock) and F-Prime Inc. (4,823 shares of Common Stock). Impresa Fund III Limited Partnership is solely managed by Impresa Management LLC, its general partner and investment manager. Impresa Management LLC is owned, directly or indirectly, by various shareholders and employees of FMR LLC, including certain members of the Johnson family. F-Prime Inc. is a wholly-owned subsidiary of FMR LLC. Read SEC document |
| March 01, 2017 Filed Mar 2, 2017 21:14 UTC | KINETA, INC./DE PTI · Entity 77778 | SaleCommon Stock | 30,000 | $14.70 | $441,000.00 |
DisclosureSEC source: 0000315066-17-002191 · primary_doc.xml · nonDerivative · entry 2 FMR LLC · CIK 0000315066 · 10% owner · See Remark 1 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 427,808 F3 · price: The price reported for this transaction is the weighted average price of multiple trades at prices ranging from $14.32 to $14.81. FMR LLC hereby undertakes to provide upon request by the Commission staff, the issuer, or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. F1 · ownership.nature: By Impresa Fund III Limited Partnership (422,985 shares of Common Stock) and F-Prime Inc. (4,823 shares of Common Stock). Impresa Fund III Limited Partnership is solely managed by Impresa Management LLC, its general partner and investment manager. Impresa Management LLC is owned, directly or indirectly, by various shareholders and employees of FMR LLC, including certain members of the Johnson family. F-Prime Inc. is a wholly-owned subsidiary of FMR LLC. Read SEC document |
| February 28, 2017 Filed Mar 2, 2017 21:14 UTC | KINETA, INC./DE PTI · Entity 77778 | SaleCommon Stock | 15,000 | $14.47 | $217,050.00 |
DisclosureSEC source: 0000315066-17-002191 · primary_doc.xml · nonDerivative · entry 1 FMR LLC · CIK 0000315066 · 10% owner · See Remark 1 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 457,808 F2 · price: The price reported for this transaction is the weighted average price of multiple trades at prices ranging from $14.20 to $14.80. FMR LLC hereby undertakes to provide upon request by the Commission staff, the issuer, or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. F1 · ownership.nature: By Impresa Fund III Limited Partnership (422,985 shares of Common Stock) and F-Prime Inc. (4,823 shares of Common Stock). Impresa Fund III Limited Partnership is solely managed by Impresa Management LLC, its general partner and investment manager. Impresa Management LLC is owned, directly or indirectly, by various shareholders and employees of FMR LLC, including certain members of the Johnson family. F-Prime Inc. is a wholly-owned subsidiary of FMR LLC. Read SEC document |
| February 27, 2017 Filed Feb 28, 2017 21:34 UTC | KINETA, INC./DE PTI · Entity 77778 | SaleCommon Stock | 15,000 | $14.65 | $219,750.00 |
DisclosureSEC source: 0000315066-17-002190 · primary_doc.xml · nonDerivative · entry 2 FMR LLC · CIK 0000315066 · 10% owner · See Remark 1 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 472,808 F3 · price: The price reported for this transaction is the weighted average price of multiple trades at prices ranging from $14.28 to $14.84. FMR LLC hereby undertakes to provide upon request by the Commission staff, the issuer, or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. F1 · ownership.nature: By Impresa Fund III Limited Partnership (467,985 shares of Common Stock) and F-Prime Inc. (4,823 shares of Common Stock). Impresa Fund III Limited Partnership is solely managed by Impresa Management LLC, its general partner and investment manager. Impresa Management LLC is owned, directly or indirectly, by various shareholders and employees of FMR LLC, including certain members of the Johnson family. F-Prime Inc. is a wholly-owned subsidiary of FMR LLC. Read SEC document |
| February 24, 2017 Filed Feb 28, 2017 21:34 UTC | KINETA, INC./DE PTI · Entity 77778 | SaleCommon Stock | 13,000 | $14.55 | $189,150.00 |
DisclosureSEC source: 0000315066-17-002190 · primary_doc.xml · nonDerivative · entry 1 FMR LLC · CIK 0000315066 · 10% owner · See Remark 1 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 487,808 F2 · price: The price reported for this transaction is the weighted average price of multiple trades at prices ranging from $14.15 to $14.88. FMR LLC hereby undertakes to provide upon request by the Commission staff, the issuer, or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. F1 · ownership.nature: By Impresa Fund III Limited Partnership (467,985 shares of Common Stock) and F-Prime Inc. (4,823 shares of Common Stock). Impresa Fund III Limited Partnership is solely managed by Impresa Management LLC, its general partner and investment manager. Impresa Management LLC is owned, directly or indirectly, by various shareholders and employees of FMR LLC, including certain members of the Johnson family. F-Prime Inc. is a wholly-owned subsidiary of FMR LLC. Read SEC document |
| December 19, 2016 Filed Dec 21, 2016 15:58 UTC | Aclaris Therapeutics, Inc. ACRS · Entity 5041 | OtherCommon Stock | 639,627 | $0.00 | $0.00 |
DisclosureSEC source: 0000315066-16-006485 · primary_doc.xml · nonDerivative · entry 1 FMR LLC · CIK 0000315066 · See Remark 1 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 1,931,727 F1 · ownership.nature: Impresa Fund III Limited Partnership (IFLP) made a pro-rata distribution to its partners, without payment of consideration, of 2,102,848 shares of Aclaris Therapeutics Inc. previously reported by FMR LLC. IFLP distributed 639,627 shares to recipients whose shares are not subject to reporting by the undersigned and 1,463,221 shares to persons and entities whose shares are subject to reporting by the undersigned. The remaining shares of common stock reported in Table I, column 5 are held by F-Prime Capital Partners Healthcare Fund III LP (456,514 shares), F-Prime Capital Partners Healthcare Advisors Fund III LP (8,765 shares), IFLP (167 shares) and F-Prime Inc. (3,060 shares). Read SEC document |
| October 26, 2016 Filed Oct 28, 2016 19:39 UTC | Aclaris Therapeutics, Inc. ACRS · Entity 5041 | SaleCommon Stock | 100 | $22.15 | $2,215.00 |
DisclosureSEC source: 0000315066-16-006303 · primary_doc.xml · nonDerivative · entry 2 FMR LLC · CIK 0000315066 · 10% owner · See Remark 1 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 2,571,354 F1 · ownership.nature: By F-Prime Capital Partners Healthcare Fund III LP (456,514 shares of Common Stock), F-Prime Capital Partners Healthcare Advisors Fund III LP (8,765 shares of Common Stock), Impresa Fund III Limited Partnership (2,103,015 shares of Common Stock) and F-Prime Inc (3,060 shares of Common Stock). The general partner of F-Prime Capital Partners Healthcare Fund III LP is F-Prime Capital Partners Healthcare Advisors Fund III LP (FPCPHA). FPCPHA and Impresa Fund III Limited Partnership are each solely managed by Impresa Management LLC, their general partner and investment manager. Impresa Management LLC is owned, directly or indirectly, by various shareholders and employees of FMR LLC, including certain members of the Johnson family. F-Prime Inc. is a wholly-owned subsidiary of FMR LLC. Read SEC document |
| October 26, 2016 Filed Oct 28, 2016 19:39 UTC | Aclaris Therapeutics, Inc. ACRS · Entity 5041 | SaleCommon Stock | 3,650 | $21.93 | $80,044.50 |
DisclosureSEC source: 0000315066-16-006303 · primary_doc.xml · nonDerivative · entry 1 FMR LLC · CIK 0000315066 · 10% owner · See Remark 1 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 2,571,454 F2 · price: The price reported for this transaction is the weighted average price of multiple trades at prices ranging from $21.86 to $22.19. FMR LLC hereby undertakes to provide upon request by the Commission staff, the issuer, or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. F1 · ownership.nature: By F-Prime Capital Partners Healthcare Fund III LP (456,514 shares of Common Stock), F-Prime Capital Partners Healthcare Advisors Fund III LP (8,765 shares of Common Stock), Impresa Fund III Limited Partnership (2,103,015 shares of Common Stock) and F-Prime Inc (3,060 shares of Common Stock). The general partner of F-Prime Capital Partners Healthcare Fund III LP is F-Prime Capital Partners Healthcare Advisors Fund III LP (FPCPHA). FPCPHA and Impresa Fund III Limited Partnership are each solely managed by Impresa Management LLC, their general partner and investment manager. Impresa Management LLC is owned, directly or indirectly, by various shareholders and employees of FMR LLC, including certain members of the Johnson family. F-Prime Inc. is a wholly-owned subsidiary of FMR LLC. Read SEC document |
| October 19, 2016 Filed Oct 20, 2016 20:20 UTC | Aclaris Therapeutics, Inc. ACRS · Entity 5041 | OtherCommon Stock | 84,223 | $0.00 | $0.00 |
DisclosureSEC source: 0000315066-16-006302 · primary_doc.xml · nonDerivative · entry 1 FMR LLC · CIK 0000315066 · 10% owner · See Remark 1 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote 1 Disclosed balance after: 2,575,104 F1 · ownership.nature: F-Prime Capital Partners Healthcare Fund III LP (FPCPH) made a pro-rata distribution to its partners, without payment of consideration, of 114,128 shares of Aclaris Therapeutics Inc. previously reported by FMR LLC. FPCPH distributed 17,079 shares to Impresa Fund III Limited Partnership (IFLP), 87,851 shares to F-Prime Capital Partners Healthcare Advisors Fund III LP (FPCPHA) and 9,198 shares to a recipient whose shares are not subject to reporting by the undersigned (an Other Recipient). FPCPHA made a pro-rata distribution to its partners, without payment of consideration, of 8,542 shares to F-Prime Inc., a wholly-owned subsidiary of FMR LLC, and 70,544 shares to Other Recipients. Finally, F-Prime Inc. made a distribution, without payment of consideration, of 4,481 shares to Other Recipients. As a result, FPCPH beneficially owns 456,514 shares, FPCPHA beneficially owns 8,765 shares, IFLP beneficially owns 2,103,015 shares and F-Prime Inc. beneficially owns 6,810 shares. Read SEC document |
| September 30, 2016 Filed Oct 11, 2016 16:25 UTC | EXA CORP EXA · Entity 169415 | GiftCommon Stock | 2,105,642 | $0.00 | $0.00 |
DisclosureSEC source: 0000315066-16-006238 · primary_doc.xml · nonDerivative · entry 1 FMR LLC · CIK 0000315066 · See Remark 1 10b5-1 filing: Not disclosed Ownership: Indirect · By Fidelity Ventures Limited Disclosed balance after: 0 Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.